2/25
11:09 am
supn
Supernus Pharmaceuticals (SUPN) was given a new $65.00 price target by Craig Hallum.
Low
Report
Supernus Pharmaceuticals (SUPN) was given a new $65.00 price target by Craig Hallum.
2/25
04:30 am
supn
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2025 Earnings Call Transcript [Seeking Alpha]
2/25
12:27 am
supn
Supernus Pharmaceuticals Inc (SUPN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
Low
Report
Supernus Pharmaceuticals Inc (SUPN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
2/24
05:32 pm
supn
Supernus Pharmaceuticals's (NASDAQ:SUPN) Q4 CY2025: Strong Sales [Yahoo! Finance]
Medium
Report
Supernus Pharmaceuticals's (NASDAQ:SUPN) Q4 CY2025: Strong Sales [Yahoo! Finance]
2/24
04:05 pm
supn
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
Medium
Report
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
2/23
06:54 pm
supn
Supernus Pharmaceuticals to Participate in March Investor Conferences [Yahoo! Finance]
Medium
Report
Supernus Pharmaceuticals to Participate in March Investor Conferences [Yahoo! Finance]
2/23
06:15 pm
supn
Supernus Pharmaceuticals to Participate in March Investor Conferences
Medium
Report
Supernus Pharmaceuticals to Participate in March Investor Conferences
2/22
10:22 pm
supn
Supernus Pharmaceuticals (SUPN) To Report Earnings Tomorrow: Here Is What To Expect [Yahoo! Finance]
Low
Report
Supernus Pharmaceuticals (SUPN) To Report Earnings Tomorrow: Here Is What To Expect [Yahoo! Finance]
2/16
09:29 am
supn
Assessing Supernus Pharmaceuticals (SUPN) Valuation After Recent Share Price Momentum And Pipeline Progress [Yahoo! Finance]
Low
Report
Assessing Supernus Pharmaceuticals (SUPN) Valuation After Recent Share Price Momentum And Pipeline Progress [Yahoo! Finance]
2/12
05:01 pm
supn
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026 [Yahoo! Finance]
Low
Report
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026 [Yahoo! Finance]
2/12
04:35 pm
supn
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
Low
Report
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
2/4
03:25 pm
supn
Lupin Launches Topiramate Extended-Release Capsules in the United States [Yahoo! Finance]
Low
Report
Lupin Launches Topiramate Extended-Release Capsules in the United States [Yahoo! Finance]
1/31
07:46 am
supn
Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/31
01:33 am
supn
Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by analysts at
Wal
Low
Report
Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by analysts at
Wal
1/26
04:18 am
supn
2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds [Yahoo! Finance]
Low
Report
2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds [Yahoo! Finance]
1/8
04:38 pm
supn
Is Supernus Pharmaceuticals (SUPN) Still Attractive After Strong Multi-Year Share Price Gains [Yahoo! Finance]
Low
Report
Is Supernus Pharmaceuticals (SUPN) Still Attractive After Strong Multi-Year Share Price Gains [Yahoo! Finance]
1/1
12:22 pm
supn
3 Low-Volatility Stocks We're Skeptical Of [Yahoo! Finance]
Low
Report
3 Low-Volatility Stocks We're Skeptical Of [Yahoo! Finance]
12/19
10:09 am
supn
Supernus Pharmaceuticals (NASDAQ:SUPN) had its price target raised by analysts at Stifel Nicolaus from $50.00 to $55.00. They now have a "hold" rating on the stock.
Low
Report
Supernus Pharmaceuticals (NASDAQ:SUPN) had its price target raised by analysts at Stifel Nicolaus from $50.00 to $55.00. They now have a "hold" rating on the stock.
12/19
07:06 am
supn
Strong Results Lifted Supernus Pharmaceuticals (SUPN) in Q3 [Yahoo! Finance]
Medium
Report
Strong Results Lifted Supernus Pharmaceuticals (SUPN) in Q3 [Yahoo! Finance]
12/16
12:23 am
supn
Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back [Yahoo! Finance]
Low
Report
Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back [Yahoo! Finance]
12/10
07:18 am
supn
Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
12/9
07:00 am
supn
Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada
Medium
Report
Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada